With high societal costs, a burgeoning market size, developers seek reimbursement for weight-loss meds

The multibillion-dollar market potential for obesity medications that analysts expect in the next decade signifies change is afoot for a patient population historically plagued with unsafe options and generally dismissed by investors and insurers.

Development, investments, partnerships climb, but safety is key

The ability of obesity medications to impact co-morbidities, reducing the symptoms and costs associated with down-the-road disease, has attracted significant attention throughout the biopharma industry.

Biopharmas focus on glucagon, amylin and other targets beyond GLP-1s

Glucagon-like peptide 1 receptor agonists have brought significant weight loss to patients, catching the attention of investors, but drug developers are continually seeking new therapies with different mechanisms to enhance the effects and improve the tolerability.